DelveInsight’s ‘Dilated Cardiomyopathy (DCM) – Market Insights, Epidemiology and Market Forecast —2030’ report delivers an in-depth understanding of the Dilated Cardiomyopathy, historical and forecasted epidemiology as well as the Dilated Cardiomyopathy market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Dilated Cardiomyopathy Overview
Cardiomyopathy is a general term that refers to the disorders of the cardiac muscle that cause mechanical or electrical dysfunction resulting in dilated, hypertrophic or restrictive pathophysiology. In Cardiomyopathy, the walls of the heart chambers become stretched, thickened or stiff; this affects the heart’s ability to pump blood around the body.
Dilated Cardiomyopathy (DCM) is characterized by left ventricular or biventricular dilation and impaired contraction, which lessens the heart effectiveness at pumping blood that is not explained by abnormal loading conditions like hypertension, valvular heart disease or coronary artery disease. It is a nonischemic heart muscle disease with structural and functional myocardial abnormalities.
Dilated Cardiomyopathy Diagnosis
The diagnosis of DCM is mainly based on the person’s symptoms, the results of a physical examination, and additional tests. Diagnosis usually includes blood test for common viruses which can cause DCM and when doctors suspect infection as an underlying cause. Additionally, electrocardiography (ECG) may detect abnormalities in the electrical activity of the heart.
Dilated Cardiomyopathy Treatment
Currently, the treatment pattern of DCM is mainly dependent on pharmacological therapy, pacing therapy, surgical options, and Corlanor (ivabradine). The pharmacological therapies consist of diuretics, inotropic agents, afterload reducing agents, beta-blockers, anticoagulation medications, anti-arrhythmia medications. The main diuretics that are prescribed for the treatment are furosemide, spironolactone, bumetanide, and metolazone.
Request for sample report for Dilated Cardiomyopathy: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights
Dilated Cardiomyopathy Epidemiology Insights
- The total prevalent cases of Dilated Cardiomyopathy in the 7MM were found to be 2,486,633 in 2017 which is expected to grow during the study period, i.e., 2017–2030.
- As per the DelveInsight analysis, the total diagnosed cases of Dilated Cardiomyopathy in the 7MM were 846,615 cases in 2017 which is expected to grow during the study period, i.e., 2017–2030.
- As per the DelveInsight analysis, the total prevalent cases of Dilated Cardiomyopathy in the United States were 1,006,256 cases in 2017 which is expected to grow during the study period, i.e., 2017–2030.
Dilated Cardiomyopathy Approved Drug
Corlanor (ivabradine): Amgen
Dilated Cardiomyopathy Emerging Drugs
PF-07265803/ARRY-371797/ARRY-797: Pfizer
Ixmyelocel-T: Vericel
BC007: Berlin Cures GmbH
Dilated Cardiomyopathy Market Outlook
According to DelveInsight, Dilated Cardiomyopathy market in the 7MM is expected to change in the study period 2017–2030. The total therapeutic market of Dilated Cardiomyopathy in seven major markets was found to be USD 244 million in 2017 which is expected to increase during the study period (2017–2030).
Download sample pages: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-dcm-market-insights
